Inflammation in Children With Attention-Deficit/Hyperactivity Disorder

Attention-Deficit/Hyperactivity Disorder Clinical Trial

— ADHD_CYTO  

Official title:

Inflammation in Children With Attention-Deficit/Hyperactivity Disorder

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT00391495
• Other study ID #: TASMC-06-NV-246-CTIL
• Status: Not yet recruiting
• Phase: N/A
• First received: October 22, 2006
• Last updated: June 18, 2007
• Start date: September 2007
• Est. completion date: December 2007

Study information

• Verified date: August 2006
• Source: Tel-Aviv Sourasky Medical Center
• Contact: Nachum Vaisman, Prof. (MD)
• Phone: 972-3-6974807
• Email: vaisman[@]tasmc.health.gov.il
• Is FDA regulated: No
• Health authority: Israel: Ethics Commission
• Study type: Observational

Clinical Trial Summary

The aim of this study is to investigate the inflammatory response in children with this disorder.

Description:

Attention deficit-hyperactivity disorder (ADHD) is a prevalent childhood neuropsychiatric disorder, characterized by age-inappropriate and impairing levels of inattention, hyperactivity and impulsiveness. Approximately 5-10% of school-age children are affected by ADHD, and in many cases, symptoms persist into adolescence and adulthood.

Cytokines are key mediators of immune function and can be either pro-inflammatory or anti-inflammatory. Recently few studies have suggested involvement of cytokine pathways in subjects with ADHD.

Polymorphism of IL-1 receptors antagonists' alleles have been suggested in families and subjects suffering from ADHD. Moreover, a new variant of inflammatory bowel disease, another immunological based disease, was recently suggested in children with ADHD and other developmental disorders. There are no other published reports on cytokine production in children who suffer from ADHD.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 45
• Est. completion date: December 2007
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 9 Years to 13 Years

Eligibility

Inclusion Criteria:

1. A defined condition of ADHD according to TOVA test (TOVA score > (-1.8), Connor's questionnaire (Connor's score > 15 points) and Achenbach's questionnaire;

2. A consent form signed by parents or legal guardianships;

Exclusion Criteria:

1. A history of any other neurological or major psychiatric disorder or other significant medical problems;

2. No current medications;

Study Design

Observational Model: Case Control, Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

• Attention Deficit Disorder with Hyperactivity
• Attention-Deficit/Hyperactivity Disorder
• Hyperkinesis

Intervention

Procedure:
• Blood drawing

Locations

Country	Name	City	State
Israel	The Unit of Clinical Nutrition	Tel Aviv

Sponsors (1)

Lead Sponsor	Collaborator
Tel-Aviv Sourasky Medical Center

Country where clinical trial is conducted

Israel,